RxDoctor Payments Data

Kimberly Warfield, MD

Family Medicine · Austin, TXNPI 1174571582

Payments from drug & device makers

$1,514in general payments, 2019–2025

Across 18 payments — averaging $84.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$454
  • Novo Nordisk$288
  • AbbVie$234
  • Bayer$125
  • Astellas Pharma US Inc$125
  • Amgen$122
  • plus $166 from 2 others

What the payments were for

  • Food & beverage$1,507100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC6$454
Novo Nordisk3$288
AbbVie(2 entities)2$234
Bayer1$125
Astellas Pharma US Inc1$125
Amgen1$122
Boehringer Ingelheim1$109
Exact Sciences3$57

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,514 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$60,996
Medicare patients
165
Services billed
778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$31,054
MounjaroTirzepatide24$24,186
Janumet XrSitagliptin Phos/Metformin Hcl17$14,059
Doxepin Hcl11$5,390
Olmesartan Medoxomil97$1,813
Rosuvastatin Calcium167$1,620
Risedronate Sodium13$1,359
Atorvastatin Calcium128$1,162
Losartan Potassium103$1,118
Metformin Hcl ErMetformin Hcl78$1,057
Levothyroxine Sodium80$1,037
Duloxetine Hcl33$897
SynthroidLevothyroxine Sodium17$731
Amlodipine Besylate115$631
Fluticasone Propionate32$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$288$31,05431 claims
Lilly USA, LLCMounjaro$454$24,18624 claims
AbbVieSynthroid$234$73117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →